Search clinical trials for: AGN-199201 ophthalmic solution

Total 1575 results

Alcon Research

Completed

Efficacy and Safety of Travoprost 0.004% Versus Tafluprost 0.0015% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension

Glaucoma
Santen Pharmaceutical Co., Ltd.

Completed

A Phase III Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost Ophthalmic Solution in Subjects With OAG or OHT

Open Angle Glaucoma or Ocular Hypertension

Singapore
Laboratorios Sophia S.A de C.V.

Completed

Safety and Tolerability of the Ophthalmic Solution PRO-179 Compared With Travatan® (PRO-179/I)

Glaucoma

Mexico
Bausch & Lomb Incorporated

Completed

Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis

Allergic Conjunctivitis

United States
Ophthalmic Consultants of Long Island
Pfizer

Completed

Exploratory Study Comparing Signs and Symptoms in Patients With Ocular Hypertension or Glaucoma Using Xalatan R® or Travatan Z®

Dry Eye Disease

United States
Allergan

Completed

Study Assessing Patient Satisfaction With LATISSE® for Increasing Eyelash Prominence

Hypotrichosis

United States
Allergan

Completed

Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children

Alopecia Areata | Eyelash Hypotrichosis

United States, Brazil
Alcon Research

Completed

Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®)

Ocular Hypertension | Glaucoma | Open-Angle Glaucoma
Allergan

Completed

Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma, Open-Angle

Canada, United States
Tulane University
Allergan

Completed

Topical Bimatoprost for Chemical Blepharoplasty

Dermatochalasis

United States
Laboratorios Sophia S.A de C.V.

Withdrawn

Safety and Tolerability of PRO-143 Ophthalmic Solution in Healthy Volunteers. (PRO-143)

Conjunctivitis, Bacterial

Mexico
Gian Sagar Medical College and Hospital

Withdrawn

Topical Bimatoprost Solution 0.03%in Stable Vitiligo

Vitiligo | Repigmentation
EyePoint Pharmaceuticals, Inc.

Completed

Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma

Primary Open Angle Glaucoma | Ocular Hypertension

United States
Silk Technologies, Ltd.

Completed

Study to Evaluate the Efficacy of SDP-4 in Subjects With Dry Eye Disease (DED) (SDP-4-CS202)

Dry Eye

United States
Laboratorios Sophia S.A de C.V.

Completed

Efficacy and Safety of PRO-148 Ophthalmic Solution Versus SYSTANE® in the Treatment of Patients With Dry Eye Syndrome (PRO-148)

Dry Eye Syndrome

Mexico
Alcon Research

Completed

Travoprost New Formulations in Patients With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-angle Glaucoma
Alcon Research

Completed

Safety and Intraocular Pressure (IOP)-Lowering Efficacy of AL-39256 in Patients With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma
Allergan

Completed

A Phase 3 Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participants With Presbyopia (GEMINI 2)

Presbyopia

United States
Allergan

Completed

Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participants With Presbyopia (GEMINI 1)

Presbyopia

United States
Peking University Third Hospital

Recruiting

The Effect of 3% Diquafosol Ophthalmic Solution on Visual Display Terminal-associated Dry Eye

Dry Eye Syndromes | Computer Vision Syndrome | Asthenopia

China
D.E.L., LLC

Unknown

Eyelash Prostheses Compared to 5.0% Lifitegrast BID for Dry Eye Disease.

Dry Eye

United States
Kukje Pharma

Not yet recruiting

A Randomized, Open-label, Active-controlled, Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of TFC-003 in Patients With Primary Open-angle Glaucoma or Ocular Hypertension

Primary Open Angle Glaucoma | Ocular Hypertension

Korea, Republic of
Tarsus Pharmaceuticals, Inc.

Completed

Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis (Saturn-1)

Blepharitis

United States
Allergan

Completed

A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Switched to Lumigan® UD Monotherapy for Medical Reasons

Ocular Hypertension | Glaucoma, Primary Open Angle

Germany
Price Vision Group

Completed

Rhopressa for Corneal Edema Associated With Fuchs Dystrophy

Fuchs Endothelial Dystrophy

United States
Stealth BioTherapeutics Inc.

Completed

A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for the Treatment of Fuchs' Corneal Endothelial Dystrophy (FCED) (SPIFD-101)

Fuchs' Corneal Endothelial Dystrophy (FCED)

United States
Noveome Biotherapeutics, formerly Stemnion
IQVIA Biotech

Terminated

ST266 Eyedrops for the Treatment of Persistent Corneal Epithelial Defects

Persistent Corneal Epithelial Defect

United States
Alcon Research

Completed

Pharmacokinetic and Safety Study of Travoprost 0.004% in Pediatric Glaucoma Patients

Ocular Hypertension | Glaucoma
Allergan

Completed

Observational Study of Lumigan® 0.01% for Treatment of Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Ocular Hypertension | Open-Angle Glaucoma

Belgium
Allgenesis Biotherapeutics Inc.
ORA, Inc.

Completed

A Study of AG-80308 in Dry Eye Patients

Dry Eye Disease

United States
Allergan

Completed

A Study of Lumigan® 0.01% in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Ocular Hypertension | Glaucoma, Open-Angle

Austria
Palatin Technologies, Inc

Recruiting

A Phase 3, Multi-Center Study Evaluating PL9643 in Patients With Dry Eye (MELODY-1)

Dry Eye | Dry Eye Syndromes

United States
Santen Pharmaceutical Co., Ltd.

Completed

DE-111 Against Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol Ophthalmic Solution 0.5%

Ocular Hypertension | Open Angle Glaucoma

Japan
Tissue Tech Inc.

Terminated

Management of Signs and Symptoms Associated With Dry Eye Disease

Dry Eye Syndromes

United States
Alcon Research

Terminated

Study of TRAVATAN in Subjects With Iris Pigmentation Changes

Ocular Hypertension | Open-Angle Glaucoma
Alcon Research

Withdrawn

Three Month Safety and Efficacy Study of TRAVATAN® Versus Travoprost Ophthalmic Solution, 0.004%

Ocular Hypertension | Open Angle Glaucoma
Dompé Farmaceutici S.p.A
Dompé US

Completed

Study to Evaluate OXERVATE™ in Patients With Stage 1 Neurotrophic Keratitis (DEFENDO)

Neurotrophic Keratitis

United States
pH Pharma

Completed

PK/PD, Safety and Tolerability of PHP-201 Topical Eye Drop in Korean and Japanese Healthy Subjects

Healthy Volunteer

Korea, Republic of
Alcon Research

Completed

Investigation of Intraocular Pressure (IOP) Reduction Efficacy of Travoprost Ophthalmic Solution in Patients With Normal Tension Glaucoma

Ocular Hypertension | Normal Tension Glaucoma

Japan
Santen Pharmaceutical Co., Ltd.

Completed

DE-111 Against Timolol Ophthalmic Solution 0.5%

Ocular Hypertension | Open Angle Glaucoma

Japan
Santen Pharmaceutical Co., Ltd.

Completed

Phase III Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye

Dry Eye

Japan
Novaliq GmbH

Completed

CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease in Subjects Who Completed CYS-004

Dry Eye Disease (DED)

United States
Tufts Medical Center
Dompé Farmaceutici S.p.A

Withdrawn

NGF Treatment for Patients With Neuropathic Corneal Pain

Neuropathy | Corneal Disease

United States
University of Maryland, Baltimore
Aerie Pharmaceuticals

Completed

Measuring the Effects of Rhopressa on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma Suspects

Ocular Hypertension | Suspect Glaucoma

United States
Shaare Zedek Medical Center

Unknown

Safety, Tolerability and Preliminary Efficacy of Unilateral Latanoprost-loaded Punctual Plug -EXP-LP (EXP-LP)

Ocular Hypertension | Glaucoma | IOP

Israel
Allergan

Completed

Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma, Open-Angle

Switzerland
Merck Sharp & Dohme LLC

Terminated

A Four Week, Open-Label Study of Azithromycin Ophthalmic Solution, 1% (P08641)

Posterior Blepharoconjunctivitis

United States
Santen Pharmaceutical Co., Ltd.

Completed

Study of DE-089 Ophthalmic Solution in Patients With Dry Eye

Dry Eye

Singapore, China
Merck Sharp & Dohme LLC

Completed

The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Four-Week Treatment Period (P08638)

Blepharitis

United States
Merck Sharp & Dohme LLC

Completed

A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Dry Eye Disease

Dry Eye Disease

United States

3

Subscribe